To better compare belimumab’s efficacy with results from phase 3 trials of obinutuzumab, investigators conducted a post hoc analysis of patients with active proliferative lupus nephritis in the MMF ...

Patients who develop LN within 1 to 5 years after SLE onset may face poorer renal outcomes compared with those who develop the disease earlier.